Inhalation Formulation Market

Demand for inhalation formulations will increase through 2036, with combination ICS and LABA therapies at 43% of the drug class segment in 2026. The market was valued at USD 43.38 billion in 2025 and is expected to be worth USD 64.69 billion by 2036, creating an incremental opportunity of USD 19.71 billion.